Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT05388201 Not yet recruiting - Healthy Clinical Trials

Variation In Facial Morphology As A Determinant Of Face Covering Performance: FACEFIT

FACEFIT
Start date: June 1, 2022
Phase:
Study type: Observational

This study examines the role of variations in the dimensions of facial features on the fitted filtering efficiency of face coverings available to the public during the COVID-19 pandemic. Approximately 100 young (18-55 years old) healthy participants will be recruited. Exclusionary criteria include pregnancy and breastfeeding. After informed consent, participants will enter a chamber where they will undergo 3D facial scanning using a dedicated camera system and be trained to don an N95 respirator properly. The fitted filtering efficiency (FFE) of 4 types of face coverings: a N95 respirator, a KN95 respirator (with and without a clip), a surgical mask (with and without a clip), and a KF94 respirator (with and without a clip) will be tested on each participant using the OSHA quantitative fit testing protocol for filtering face pieces.

NCT ID: NCT05387759 Not yet recruiting - Healthy Clinical Trials

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effects of aticaprant on QT/ QT interval corrected for heart rate (HR) (QTc) intervals and electrocardiogram (ECG) morphology at therapeutic and supratherapeutic exposures in healthy adult participants.

NCT ID: NCT05386823 Terminated - Healthy Clinical Trials

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

Start date: March 27, 2021
Phase: Phase 1
Study type: Interventional

HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the induction of remission in patients with acute promyelocytic leukemia (APL) and for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs). This phase 1 Trial is a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HF1K16.

NCT ID: NCT05385718 Not yet recruiting - Healthy Clinical Trials

Ezra Faster Scan Study

FasterScan
Start date: May 30, 2022
Phase:
Study type: Observational

The Ezra Faster Scan study uses non-invasive magnetic resonance imaging (MRI) technology that can "visually" detect early and late-stage cancer, and other pathologies. MRIs use a magnetic field and radio waves to create a 3-dimensional (3D) image of an individual's body without using ionizing radiation. The purpose of this research is to decrease the amount of time required by an individual to complete an early cancer screening comprehensive magnetic resonance imaging (MRI) scan, such as the Ezra Full Body MRI imaging scan. If the time required to conduct a comprehensive scan is reduced, the cost of the scan may also decrease. By decreasing consumer costs and time, more individuals may be able to afford MRI-based early cancer screening technology. Participants in this study will undergo a minimum 30-minute MRI session. These sessions will be used to evaluate new MRI "instructions" that allow for a faster MRI scan time. The images will also be used to develop mathematical models or machine learning tools that allow images to be enhanced. By enhancing images using machine learning, they may be restored to a quality typically observed in MRI sessions with longer scan (acquisition) times. To read more about the study, potential participants may review the informed consent form located below in the References section. Potential participants may also book an appointment with study personnel to hear more about this study at https://calendly.com/ezra-research/ezra-faster-scan-research-study-information-session, email [email protected], or call 516.340.1221. See study Eligibility Criteria below. If eligible, potential participants may complete a prescreening questionnaire following these links. If a resident of California, https://login.redcapcloud.com/survey.jsp?code=EfFaBdfx9iGYWRWB. If a resident of New York, or Florida, https://login.redcapcloud.com/survey.jsp?code=QZMTDPxZnAK3Mchq.

NCT ID: NCT05384678 Not yet recruiting - Healthy Clinical Trials

Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study

DMT DR
Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

N,N-dimethyltryptamine (DMT) is a psychoactive substance with similar effects such as LSD or psilocybin. However, DMT is less well characterized than the latter substances. The present study is a modern randomized cross-over trial, investigating different continuous intravenous DMT dose rates over a broad dose range. Thus, different doses will be tested and related to subjective and autonomic effects.

NCT ID: NCT05384301 Not yet recruiting - Healthy Clinical Trials

Effects of Urban Afforestation Activity on Mood, Stress, and Anxiety

Start date: May 25, 2022
Phase: N/A
Study type: Interventional

This single-group pretest-posttest clinical trial aims to evaluate the effects of a single-session afforestation activity on mood, stress, and anxiety in a sample of adults.

NCT ID: NCT05384106 Not yet recruiting - Healthy Clinical Trials

AN OPEN-LABEL, ACUTE CLINICAL TRIAL TO ASSESS THE LEVEL OF KETONE PRODUCTION FOLLOWING CONSUMPTION OF AVELA™ (R)-1,3-BUTANEDIOL IN AN ADULT POPULATION

Start date: May 25, 2022
Phase: N/A
Study type: Interventional

The purpose of the pilot clinical trial described herein is to determine the level of ketone production [measured as β hydroxybutyrate (BHB)] following consumption of (R)-1,3-butanediol in a beverage and to record gastrointestinal (GI) symptomology, as well as any effects on alertness/sleepiness.

NCT ID: NCT05382793 Recruiting - Healthy Clinical Trials

Assessment of the Daily Average Requirement of Iodine in Lactating Women

LISA
Start date: May 16, 2022
Phase: N/A
Study type: Interventional

Human milk is the only source of iodine during early infancy and adequate iodine intake during lactation is necessary to assure optimal thyroid function in breastfed infants. However, the physiological requirement of iodine in lactating women is uncertain and recommendations for the daily dietary average requirement are poorly defined. WHO recommends iodine supplementation to lactating women in populations with incomplete coverage of iodized salt and deficient iodine intake, but the scientific evidence is weak and the optimal dose is uncertain. The primary objective is to assess the daily dietary average requirement for iodine in lactating women. Secondary objectives are to: - Estimate the daily average requirement for iodine in exclusively breastfed infants; - Assess the dose-response of dietary iodine supplements on breast milk iodine concentration in lactating women with adequate and inadequate habitual iodine intakes; - Estimate the maternal iodine intake required to provide exclusively breastfed infants with an adequate iodine intake via breast milk.

NCT ID: NCT05380947 Not yet recruiting - Healthy Clinical Trials

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Start date: May 30, 2022
Phase: Phase 1
Study type: Interventional

BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, and intended commercial formulation (iCF) is planned to be used in the future in clinical trials and on the market. This trial intends to bridge pharmacokinetics (PK) between the two formulations. Moreover the trial intends to inform on the effect of food and of the proton pump inhibitor rabeprazole on the PK of BI 1810631 in order to inform management of food and concomitant medications.

NCT ID: NCT05380323 Recruiting - Healthy Clinical Trials

A Study of LY3541105 in Healthy and Overweight Participants

Start date: May 10, 2022
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it takes the body to eliminate it. The study will also evaluate the effects of LY3541105 on body weight. This is a 2-part study and may last up to 15 and 26 weeks for each participant and may include up to 7 and 15 visits in parts A and B, respectively.